A detailed history of Pnc Financial Services Group, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 4,843 shares of VKTX stock, worth $319,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,843
Previous 3,583 35.17%
Holding current value
$319,008
Previous $293,000 12.63%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$47.39 - $80.2 $59,711 - $101,052
1,260 Added 35.17%
4,843 $256,000
Q1 2024

May 10, 2024

BUY
$17.4 - $94.5 $44,857 - $243,621
2,578 Added 256.52%
3,583 $293,000
Q4 2023

Feb 09, 2024

BUY
$9.24 - $19.64 $46 - $98
5 Added 0.5%
1,005 $18,000
Q3 2023

Nov 13, 2023

SELL
$10.92 - $16.0 $7,305 - $10,704
-669 Reduced 40.08%
1,000 $11,000
Q2 2023

Aug 11, 2023

BUY
$14.84 - $24.79 $9,927 - $16,584
669 Added 66.9%
1,669 $27,000
Q3 2022

Nov 10, 2022

SELL
$2.55 - $3.89 $5,043 - $7,694
-1,978 Reduced 66.42%
1,000 $2,000
Q2 2022

Aug 12, 2022

BUY
$2.11 - $3.15 $4,173 - $6,230
1,978 Added 197.8%
2,978 $8,000
Q4 2021

Feb 11, 2022

SELL
$4.6 - $6.72 $4,600 - $6,720
-1,000 Reduced 50.0%
1,000 $4,000
Q2 2021

Aug 06, 2021

BUY
$5.19 - $6.73 $2,595 - $3,365
500 Added 33.33%
2,000 $11,000
Q1 2021

May 07, 2021

BUY
$5.74 - $9.67 $2,870 - $4,835
500 Added 50.0%
1,500 $9,000
Q4 2020

Feb 12, 2021

SELL
$5.3 - $6.71 $23,850 - $30,195
-4,500 Reduced 81.82%
1,000 $5,000
Q3 2020

Nov 06, 2020

BUY
$5.73 - $8.11 $25,785 - $36,495
4,500 Added 450.0%
5,500 $32,000
Q1 2020

May 08, 2020

SELL
$3.45 - $7.95 $1,897 - $4,372
-550 Reduced 35.48%
1,000 $4,000
Q1 2019

May 10, 2019

BUY
$7.58 - $9.94 $9,475 - $12,425
1,250 Added 416.67%
1,550 $0
Q3 2018

Nov 09, 2018

BUY
$9.7 - $19.65 $2,910 - $5,895
300 New
300 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.